<DOC>
	<DOCNO>NCT01596699</DOCNO>
	<brief_summary>The purpose study find effect , good and/or bad , addition clofarabine , new chemotherapy agent , standard busulfan fludarabine conditioning treatment . The study also look cause people high drug level medication body compare people may low drug level even receive dose medication .</brief_summary>
	<brief_title>Pilot Trial Clofarabine Added Standard Busulfan Fludarabine Conditioning Prior Allogeneic Hematopoietic Cell Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Metabolic Diseases</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<mesh_term>Hemoglobinuria , Paroxysmal</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients must ≥ 3 month ≤30 year age . Stratum A : NonMalignant Diseases , include : Bone Marrow Failure Syndromes Hemoglobinopathies transfusiondependent RBC defect Congenital Immunodeficiencies Metabolic Diseases know treatable HCT ( e.g . Hurler 's ) Other Bone Marrow Stem Cell Defects ( e.g . Osteopetrosis ) Severe Immune Dysregulation / Autoimmune Syndromes least transient prior response immunosuppressive therapy Stratum B : Myeloid Malignancies , include : AML , great first clinical remission , CR1 detectable disease ( ≥0.1 % Blasts MRD Flow , Positive Cytogenetics ) , CR1 match sibling UCB donor . MDS JMML CML , detectable disease PCR Patients must suitable donor base UCSF Pediatric BMT SOP . 10/10 ( HLAA , B , C , DR , DQ ) match do related adult unrelated donor ; 8/8 ( HLAA , B , C , DR ) umbilical cord blood donor . Patients nonmalignant disease generally eligible mismatch donor , accept clinical reason consider highrisk rejection . Liver transaminases ( AST/ALT ) Direct Bilirubin less twice upper limit normal within 2 week admission . Cardiac Shortening Fraction ≥27 % within 4 week admission . Creatinine clearance Schwartz formula , GFR 24 hr urine collection ≥50 cc/min/1.73 m2 , within 4 week admission . Pulmonary diffusion capacity ≥50 % predict corrected anemia/lung volume within 4 week admission . If unable PFT 's , active lung disease CXR and/or O2 Sat ≥90 % room air . Fanconi Anemia Dyskeratosis Congenita A known syndrome increase sensitivity radiation alkylating agent Severe Combined Immunodeficiency Disease eligible nonmyeloablative HCT trial A mismatch donor ex vivo Tcell depletion donor stem cell plan</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>conditioning</keyword>
	<keyword>allogeneic</keyword>
	<keyword>hematopoietic</keyword>
	<keyword>cell</keyword>
	<keyword>transplantation</keyword>
	<keyword>HCT</keyword>
</DOC>